Why Is IOVANCE BIOTHERAPEUT (IOVA) Stock Up Today?
By the Top Tier Newswire AI Desk · August 6, 2026 at 1:24 PM ET · reviewed against 8 wire stories
IOVANCE BIOTHERAPEUT (IOVA) is up +41.13% in the latest session. Our newswire has captured 8 stories on IOVA across 7 sources in the last 36 hours, with AI sentiment reading bullish (avg 69/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
IOVA stock surged 41.13% to $6.13 in Thursday's session driven by record second-quarter revenue and positive developments in its clinical pipeline. The biotech firm reported $99.3 million in revenue for Q2 2026, a 66% year-over-year increase, fueled by strong demand for its cancer therapy Amtagvi. The company also announced a new early-stage trial for IOV-5001 TIL, expanding its solid tumor pipeline.
What Happened
Iovance Biotherapeutics reported Q2 revenue of $99.3 million, exceeding expectations and marking a new high for the company. The results were driven by robust sales of Amtagvi, which generated $91 million in U.S. revenue alone. The company also announced a new early-stage clinical trial for IOV-5001 TIL, aimed at expanding its pipeline into solid tumors. These developments, combined with a revised 2026 revenue outlook, contributed to the sharp rise in the stock. An 8-K filing on August 6 disclosed the financial results and operational updates, including a 56% gross margin and continued clinical progress.
What The Data Shows
The stock opened at $4.39, a 1.1% gap up from the prior close, and reached an intraday high of $6.39 shortly after the market opened. The session low was $4.39, and the stock closed the session at $6.13. Trading volume reached 47.8 million shares, significantly above the 3-month daily average by a factor of 3.2. Over the past 8 sessions, the stock has gained 24.0%, moving from $4.70 to $5.83. The 30-day average sentiment score is 63 out of 100, improving to 69 in the last 7 days.
What To Watch
The company affirmed its FY2026 sales guidance of $350 million to $370 million, and the market will continue to monitor its progress in clinical trials and global expansion. Investors should also track the company’s next major corporate updates and any further guidance revisions.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
IOVA · Aug 6 session (5-min) · +42.17% vs prior close · updated 8:44 PM ETAI sentiment, last 36h · averaged over 8 stories · 69/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
4d agoTipRanksBULLISH 63Product/PR
Iovance Expands Solid Tumor Pipeline With New IOV-5001 TIL Trial
Iovance Biotherapeutics ($IOVA) announced an update on their ongoing clinical study. Iovance Biotherapeutics, Inc. is launching a new early-stage trial called “A Ph...
4d agoStocktwits NewsBULLISH 73Earnings
IOVA Stock Heads For Best Day In Over 6 Years – Buyout Buzz Builds After Blowout Q2
The biotech company reported record second-quarter revenue fueled by strong sales of its cancer therapy Amtagvi.
4d agoInvestorsHubBULLISH 73Earnings
Iovance Biotherapeutics Reports Record Q2 Revenue and Reviews 2026 Outlook on Strong Amtagvi Demand
Iovance Biotherapeutics reported record Q2 2026 revenue of $99.3 million, improved margins and strong Amtagvi demand, prompting a review of its full-year revenue guidance while advancing multiple late-stage clinical programmes.
4d agoMarketChameleonBULLISH 76Earnings
IOVA Delivers Record $99 Million Revenue on Surging Amtagvi Demand and Expanding Global Footprint
Iovance Biotherapeutics posts a record-breaking second quarter with $99 million in revenue, fueled by soaring Amtagvi demand and robust commercial expansion. Strong gross margins and a growing clinical pipeline highlight accelerating market momentum, as Iovance signals potential upward guidance revisions ahead.
4d agoSeeking AlphaBULLISH 73Earnings
Iovance surges as Amtagvi powers Q2 beat
Iovance (IOVA) stock surges as the company posted Q2 2026 results that well surpassed Street forecasts driven by its cancer therapy, Amtagvi. Read more here.
4d agoMarketChameleonBULLISH 73Earnings
Iovance Biotherapeutics Delivers Record $99M Quarterly Revenue and Expands Amtagvi’s Global Footprint Amid Pipeline Advances
August 6, 2026
Iovance Biotherapeutics hits a record second-quarter 2026 revenue of $99 million, with a 56% gross margin, driven by strong Amtagvi demand and expanding international approvals. Clinical pipeline advances, operational efficiencies, and an updated guidance review highlight the company's momentum.
4d agoSEC 8-KNEUTRAL 50General
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) files 8-K
Filed: 2026-08-06 AccNo: 0001104659-26-091619 Size: 309 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
4d agoStockTitanBULLISH 67Earnings
Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates
U.S. Amtagvi Revenue Reaches ~$91M and Total Revenue Increased 66% Year-over-Year Gross Margin Increased to 56% Fast Track Designation (FTD) Granted by the FDA for Lifileucel...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →